Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDTX NASDAQ:ENGN NASDAQ:PYXS NASDAQ:SNTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$1.75-3.8%$2.60$1.75▼$4.94$104.29M3.222.17 million shs2.31 million shsENGNenGene$1.62-1.2%$4.41$1.40▼$12.25$109.86M-0.31.15 million shs456,532 shsPYXSPyxis Oncology$1.76+5.4%$1.85$0.97▼$5.55$105.80M1.42502,299 shs437,524 shsSNTISenti Biosciences$0.96-2.5%$0.97$0.77▼$3.40$30.66M2.08184,540 shs76,350 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics-1.62%-13.13%-35.69%-14.15%-23.21%ENGNenGene+2.50%-4.65%+13.89%-77.09%-49.07%PYXSPyxis Oncology0.00%-2.34%-35.77%+8.44%+30.47%SNTISenti Biosciences+2.54%-1.55%+1.49%+5.69%-64.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$1.75-3.8%$2.60$1.75▼$4.94$104.29M3.222.17 million shs2.31 million shsENGNenGene$1.62-1.2%$4.41$1.40▼$12.25$109.86M-0.31.15 million shs456,532 shsPYXSPyxis Oncology$1.76+5.4%$1.85$0.97▼$5.55$105.80M1.42502,299 shs437,524 shsSNTISenti Biosciences$0.96-2.5%$0.97$0.77▼$3.40$30.66M2.08184,540 shs76,350 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics-1.62%-13.13%-35.69%-14.15%-23.21%ENGNenGene+2.50%-4.65%+13.89%-77.09%-49.07%PYXSPyxis Oncology0.00%-2.34%-35.77%+8.44%+30.47%SNTISenti Biosciences+2.54%-1.55%+1.49%+5.69%-64.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDTXBlack Diamond Therapeutics 2.73Moderate Buy$10.00471.43% UpsideENGNenGene 2.21Hold$12.68682.83% UpsidePYXSPyxis Oncology 2.63Moderate Buy$6.83288.26% UpsideSNTISenti Biosciences 2.75Moderate Buy$10.00941.45% UpsideCurrent Analyst Ratings BreakdownLatest SNTI, ENGN, BDTX, and PYXS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2026PYXSPyxis Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026BDTXBlack Diamond Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/22/2026BDTXBlack Diamond Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/22/2026BDTXBlack Diamond Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/21/2026PYXSPyxis Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/18/2026BDTXBlack Diamond Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/15/2026ENGNenGene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026SNTISenti Biosciences Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$11.00 ➝ $12.005/14/2026ENGNenGene UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$9.00 ➝ $2.005/8/2026ENGNenGene Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$4.005/8/2026ENGNenGene Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$7.00 ➝ $4.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDTXBlack Diamond Therapeutics$70M1.43$0.51 per share3.45$1.97 per share0.89ENGNenGeneN/AN/AN/AN/A$2.60 per shareN/APYXSPyxis Oncology$13.86M8.04N/AN/A$0.86 per share2.05SNTISenti Biosciences$20K1,495.51N/AN/A$0.18 per share5.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDTXBlack Diamond Therapeutics$22.37M-$0.77N/AN/AN/AN/A-30.18%-23.91%8/6/2026 (Estimated)ENGNenGene-$117.30M-$2.25N/AN/AN/AN/A-55.83%-45.74%N/APYXSPyxis Oncology-$79.62M-$1.31N/AN/AN/AN/A-135.60%-85.00%8/13/2026 (Estimated)SNTISenti Biosciences-$61.44M-$1.92N/AN/AN/AN/A-532.05%-103.35%8/6/2026 (Estimated)Latest SNTI, ENGN, BDTX, and PYXS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026PYXSPyxis Oncology-$0.35-$0.37-$0.02-$0.37$0.02 millionN/A5/14/2026Q1 2026SNTISenti Biosciences-$0.36-$0.14+$0.22-$0.14$0.02 million$0.02 million5/7/2026Q1 2026BDTXBlack Diamond Therapeutics-$0.18-$0.16+$0.02-$0.16$25.00 millionN/A3/27/2026Q4 2025SNTISenti Biosciences-$0.43-$0.53-$0.10-$0.53$1.00 millionN/A3/23/2026Q4 2025PYXSPyxis Oncology-$0.35-$0.29+$0.06-$0.29$0.13 million$11.04 million3/16/2026Q4 2025BDTXBlack Diamond Therapeutics-$0.18-$0.14+$0.04-$0.27$9.38 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/AENGNenGeneN/AN/AN/AN/AN/APYXSPyxis OncologyN/AN/AN/AN/AN/ASNTISenti BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDTXBlack Diamond TherapeuticsN/A8.468.46ENGNenGene0.0911.7511.75PYXSPyxis OncologyN/A2.762.76SNTISenti BiosciencesN/A1.041.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDTXBlack Diamond Therapeutics95.47%ENGNenGene64.16%PYXSPyxis Oncology39.07%SNTISenti Biosciences25.70%Insider OwnershipCompanyInsider OwnershipBDTXBlack Diamond Therapeutics9.29%ENGNenGene10.50%PYXSPyxis Oncology10.60%SNTISenti Biosciences3.12%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDTXBlack Diamond Therapeutics9057.30 million51.98 millionOptionableENGNenGene3166.99 million59.95 millionN/APYXSPyxis Oncology6063.35 million56.64 millionOptionableSNTISenti Biosciences431.15 million30.17 millionNot OptionableSNTI, ENGN, BDTX, and PYXS HeadlinesRecent News About These CompaniesSenti Biosciences (NASDAQ:SNTI) Stock Price Down 3.8% - What's Next?June 10 at 2:29 AM | americanbankingnews.comSenti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note StructureMay 16, 2026 | tipranks.comSenti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important ...May 14, 2026 | markets.businessinsider.comSenti Biosciences Secures Up to $40 Million Financing and FDA Endorsement for SENTI-202 in Relapsed/Refractory Acute Myeloid LeukemiaMay 14, 2026 | quiverquant.comQSenti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal PhaseMay 14, 2026 | globenewswire.comSenti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical ProgramMay 14, 2026 | globenewswire.comSenti Biosciences Holdings Inc.May 13, 2026 | barrons.comSenti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026April 13, 2026 | markets.businessinsider.comSenti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026April 13, 2026 | globenewswire.comSenti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell TherapiesApril 1, 2026 | globenewswire.comSenti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate UpdateMarch 27, 2026 | globenewswire.comSenti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer ConferenceMarch 23, 2026 | globenewswire.comSenti Biosciences Amends Lease, Restructures GeneFab SubleaseMarch 19, 2026 | tipranks.comSenti Biosciences to Present at Leerink Partners 2026 Global Healthcare ConferenceMarch 3, 2026 | tmcnet.comSenti Biosciences to Present at Leerink Partners 2026 Global Healthcare ConferenceMarch 3, 2026 | globenewswire.comSenti Biosciences to Showcase Gene Circuit Technology and Partnership Opportunities at TD Cowen Health Care ConferenceFebruary 24, 2026 | quiverquant.comQSenti Biosciences to Present at TD Cowen 46th Annual Health Care ConferenceFebruary 24, 2026 | globenewswire.comSenti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy DevelopmentFebruary 20, 2026 | globenewswire.comSenti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)February 11, 2026 | globenewswire.comSenti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026February 3, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNTI, ENGN, BDTX, and PYXS Company DescriptionsBlack Diamond Therapeutics NASDAQ:BDTX$1.75 -0.07 (-3.85%) Closing price 04:00 PM EasternExtended Trading$1.80 +0.04 (+2.57%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.enGene NASDAQ:ENGN$1.62 -0.02 (-1.22%) Closing price 04:00 PM EasternExtended Trading$1.63 +0.01 (+0.62%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Pyxis Oncology NASDAQ:PYXS$1.76 +0.09 (+5.39%) Closing price 04:00 PM EasternExtended Trading$1.76 -0.01 (-0.28%) As of 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.Senti Biosciences NASDAQ:SNTI$0.96 -0.02 (-2.47%) Closing price 04:00 PM EasternExtended Trading$0.98 +0.02 (+1.75%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
